Literature DB >> 8390009

Calcium acetate versus calcium carbonate as phosphorus binders in patients on chronic haemodialysis: a controlled study.

T Ring1, C Nielsen, S P Andersen, J K Behrens, B Sodemann, H J Kornerup.   

Abstract

The first reported double-blind cross-over comparison between the phosphorus binders calcium carbonate and calcium acetate was undertaken in 15 stable patients on chronic maintenance haemodialysis. Detailed registration of diet and analysis of the protein catabolic rate suggested an unchanged phosphorus intake during the study. It was found that predialytic serum phosphate concentration was significantly decreased by 0.11 mmol/l (0.34 mg/dl) (P = 0.021, 95% confidence limits 0.02-0.21 mmol/l; 0.06-0.65 mg/dl) during calcium acetate treatment. The calcium phosphate product was insignificantly decreased during treatment with calcium acetate whereas we could not exclude the possibility that calcium concentration had increased.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8390009

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  7 in total

Review 1.  Minimizing bone abnormalities in children with renal failure.

Authors:  Helena Ziólkowska
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

2.  Calcium acetate versus calcium carbonate as oral phosphate binder in pediatric and adolescent hemodialysis patients.

Authors:  M Wallot; K E Bonzel; A Winter; B Geörger; B Lettgen; M Bald
Journal:  Pediatr Nephrol       Date:  1996-10       Impact factor: 3.714

Review 3.  Management of hyperphosphataemia in dialysis patients: role of phosphate binders in the elderly.

Authors:  Víctor Lorenzo Sellares; Armando Torres Ramírez
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 4.  Safety of new phosphate binders for chronic renal failure.

Authors:  Mahmoud Loghman-Adham
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

5.  Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability.

Authors:  Angel L M de Francisco; Michael Leidig; Adrian C Covic; Markus Ketteler; Ewa Benedyk-Lorens; Gabriel M Mircescu; Caecilia Scholz; Pedro Ponce; Jutta Passlick-Deetjen
Journal:  Nephrol Dial Transplant       Date:  2010-06-07       Impact factor: 5.992

6.  Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).

Authors:  Marinella Ruospo; Suetonia C Palmer; Patrizia Natale; Jonathan C Craig; Mariacristina Vecchio; Grahame J Elder; Giovanni Fm Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2018-08-22

7.  Calcium acetate or calcium carbonate for hyperphosphatemia of hemodialysis patients: a meta-analysis.

Authors:  Yong Wang; Guoqiang Xie; Yuanhang Huang; Han Zhang; Bo Yang; Zhiguo Mao
Journal:  PLoS One       Date:  2015-03-23       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.